Skip to content

Evaluating the value of neuromechanical assessment in spasticity treatment

Evaluating the value of neuromechanical assessment in spasticity treatment - ASSIST

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53571
Enrollment
150
Registered
2023-03-02
Start date
2025-09-17
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral paresis stroke

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Visiting the outpatient clinic in Rijndam Rehabilitation Center, Erasmus MC, or Amsterdam UMC (location VUmc) to seek treatment of spasticity of the upper extremity. - >=18 years; - Minimal passive range of motion (PROM) in shoulder joint: 0-80° abduction, 0-45° anterior flexion. - At least some volitional control of elbow flexion and extension; - Having given written informed consent prior to undertaking any study-related procedures.

Exclusion criteria

Exclusion criteria: - Inability to understand instructions (for example due to intellectual impairment); - History of pre-existing neuromusculoskeletal disorders that would influence the upper extremity function (e.g., presence of a prosthetics shoulder, other neurological condition which might affect upper extremity function, surgery/specific treatment

Design outcomes

Primary

MeasureTime frame
1. Relation between pre-treatment muscle weakness, spasticity, abnormal synergies, and changes in viscoelastic joint properties and treatment outcome quantified by change spasticity with a multivariable regression analysis, correcting for several patient characteristics. 2. Responsiveness to treatment, quantified as the standardized mean difference, of muscle weakness, spasticity, synergy, and viscoelasticity of the elbow measured with the SEP.

Secondary

MeasureTime frame
N.A.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)